Endocrine Pharmacology: Insulin Preparations and Mechanism

Introduction/Overview

Insulin remains the cornerstone of therapy for patients with diabetes mellitus, a chronic metabolic disorder characterized by impaired glucose regulation. The clinical relevance of insulin pharmacology is underscored by the global prevalence of diabetes, the high morbidity associated with hyperglycaemia, and the necessity for precise glycaemic control to prevent long‑term complications such as retinopathy, nephropathy, and neuropathy. An in‑depth understanding of insulin preparations, their pharmacodynamics, pharmacokinetics, and clinical nuances is essential for both medical and pharmacy professionals engaged in diabetes management.

Learning objectives:

• Identify the major classes of insulin preparations and their chemical characteristics.
• Describe the receptor‑mediated mechanisms by which insulin exerts its metabolic effects.
• Explain the absorption, distribution, metabolism, and excretion profiles of various insulin analogues.
• Correlate insulin pharmacokinetics with dosing strategies and therapeutic goals.
• Recognise potential adverse effects, drug interactions, and special considerations in vulnerable populations.

Classification

Traditional Insulin Preparations

• Rapid‑acting insulin – e.g., regular human insulin, first‑generation analogues such as insulin lispro and insulin aspart.
• Short‑acting insulin – e.g., regular human insulin with a delayed onset.
• Intermediate‑acting insulin – e.g., NPH (neutral protamine Hagedorn) insulin.
• Long‑acting insulin – e.g., insulin glargine, insulin detemir.
• Ultra‑long‑acting insulin – e.g., insulin degludec.

Insulin Analogue Derivatives

Insulin analogues have been engineered through amino‑acid substitutions or addition of fatty‑acid chains to modulate absorption rates and receptor binding affinity. The chemical modifications are summarised below:

• Rapid‑acting analogues – typically involve substitution at the B29 position (e.g., lispro: lysine↔proline) or addition of a fatty‑acid chain to enhance membrane interaction (e.g., aspart: serine↔aspartic acid).
• Long‑acting analogues – involve modification of the insulin molecule to prolong half‑life and reduce peak‑to‑trough variability (e.g., glargine: addition of two arginine residues extends the isoelectric point; detemir: addition of a fatty‑acid chain increases albumin binding).
• Ultra‑long‑acting analogue – degludec forms multi‑hexamer chains in the subcutaneous depot, allowing a self‑sustained release profile.

Pharmaceutical Formulations

Insulin preparations are delivered primarily via subcutaneous injection, though inhaled formulations (e.g., insulin lispro as inhalable powder) are available for rapid‑acting insulin. Injections can be administered using pens, syringes, or autosyringe devices, each offering distinct advantages in terms of convenience, dosing precision, and patient adherence.

Mechanism of Action

Receptor Interactions

Insulin exerts its effects by binding to the insulin receptor (INSR), a transmembrane tyrosine kinase receptor composed of two extracellular α‑subunits and two transmembrane β‑subunits. The binding of insulin to the α‑subunits induces a conformational change that activates the intracellular β‑subunit kinase domain. Phosphorylation of tyrosine residues on the receptor triggers downstream signalling cascades, notably the phosphatidylinositol‑3‑kinase (PI3K) pathway and the mitogen‑activated protein kinase (MAPK) pathway. The PI3K pathway is primarily responsible for metabolic actions, whereas the MAPK pathway mediates mitogenic effects. The activation of the PI3K pathway leads to the translocation of glucose transporter type 4 (GLUT4) to the plasma membrane in adipose and skeletal muscle cells, thereby facilitating glucose uptake. Simultaneously, insulin suppresses hepatic gluconeogenesis and glycogenolysis, enhances glycogen synthesis, and promotes lipogenesis while inhibiting lipolysis.

Molecular and Cellular Mechanisms

• Glucose Uptake – In adipocytes and myocytes, insulin‑stimulated GLUT4 translocation increases transmembrane glucose transport, resulting in a rapid decline in circulating glucose levels.
• Hepatic Glycogen Synthesis – Insulin activates glycogen synthase via dephosphorylation, while inactivating glycogen phosphorylase, thereby promoting glycogen storage.
• Protein Synthesis – Insulin activates the mammalian target of rapamycin (mTOR) signalling, stimulating amino‑acid uptake and protein synthesis.
• Lipid Metabolism – Insulin up‑regulates fatty‑acid synthase (FAS) and down‑regulates hormone‑sensitive lipase (HSL), promoting lipogenesis and reducing lipolysis.
• Renal Sodium Handling – Insulin augments sodium reabsorption in the proximal tubule, contributing to fluid retention and blood pressure modulation.

Pharmacokinetics

Absorption

• Rapid‑acting analogues – onset of action within 10–15 minutes, peak effect between 30–90 minutes, duration 3–5 hours. Absorption is largely dependent on the injection technique and local perfusion.
• Intermediate‑acting insulin – onset approximately 1–2 hours, peak at 4–6 hours, duration 10–12 hours.
• Long‑acting insulin – onset 1–2 hours, no pronounced peak, duration 20–24 hours (glargine) or 18–20 hours (detemir).
• Ultra‑long‑acting insulin – onset 1–2 hours, minimal or no peak, duration up to 42 hours (degludec).

Distribution

Insulin is a hydrophilic peptide with a molecular weight of approximately 5800 Daltons. Following subcutaneous injection, it distributes primarily within the interstitial fluid and subsequently enters the systemic circulation. The volume of distribution approximates total body water, reflecting limited extravascular binding.

Metabolism

Insulin is metabolised by proteolytic enzymes, primarily in the liver and kidneys. The half‑life of insulin in plasma is short (approximately 4–5 minutes), but prolonged duration of action is achieved through depot formation or modification of the insulin molecule to resist rapid degradation.

Excretion

Renal excretion of intact insulin is minimal; instead, insulin is largely metabolised to inactive peptides. In patients with severe renal impairment, degradation may be slowed, potentially prolonging action, particularly for insulins with longer half‑lives.

Half‑life and Dosing Considerations

• Rapid‑acting analogues: 1–2 hours; dosing often aligned with meals.
• Intermediate‑acting insulin: 10–12 hours; typically administered once or twice daily.
• Long‑acting insulin: 20–24 hours; once daily dosing is common.
• Ultra‑long‑acting insulin: up to 42 hours; allows flexibility in dosing intervals, potentially reducing hypoglycaemia risk.

Therapeutic Uses/Clinical Applications

Approved Indications

Insulin preparations are indicated for the management of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) requiring exogenous insulin therapy. Rapid‑acting analogues are primarily used for postprandial glucose control, while basal insulin analogues provide background glycaemic control. Combination preparations (e.g., basal‑bolus regimens) are employed to mimic physiological insulin secretion patterns.

Off‑Label Uses

• Insulin glargine has been investigated for use in gestational diabetes when other agents fail to achieve glycaemic targets.
• High‑dose insulin infusion is employed in the management of severe hypoglycaemia and in the treatment of insulin‑receptor‑deficient states.
• Insulin has been used in the acute management of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS) in conjunction with fluid resuscitation and electrolyte correction.

Adverse Effects

Common Side Effects

• Hypoglycaemia – the most frequent adverse event, ranging from mild neuroglycopenic symptoms to severe neurovisceral manifestations.
• Weight gain – secondary to increased glycogen and fat storage.
• Injection‑site reactions – erythema, induration, and pruritus.
• Edema – particularly with long‑acting insulin analogues due to sodium retention.

Serious or Rare Adverse Reactions

• Insulin resistance – may develop with chronic exposure, necessitating dose escalation.
• Allergic reactions – rare hypersensitivity to insulin or excipients.
• Pancreatic β‑cell dysfunction – theoretical but not conclusively linked to long‑term insulin therapy.
• Exogenous insulin‑induced lipodystrophy – localized fat redistribution at injection sites.

Black Box Warnings

None of the currently marketed insulin preparations carry a black box warning. However, the potential for life‑threatening hypoglycaemia mandates vigilant monitoring and patient education.

Drug Interactions

Major Drug-Drug Interactions

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may increase insulin sensitivity, leading to hypoglycaemia.
• Beta‑blockers – can mask hypoglycaemic symptoms and reduce counter‑regulatory hormone release.
• Thyroid hormones – thyroid dysfunction alters insulin requirements; hyperthyroidism increases insulin sensitivity, hypothyroidism decreases it.
• Alcohol – increases hypoglycaemic risk, especially with prolonged fasting.
• Metformin – synergistic effect on glycaemic control; risk of lactic acidosis is elevated in renal impairment.

Contraindications

Insulin therapy is contraindicated in patients with known hypersensitivity to the insulin molecule or its excipients. Caution is advised in individuals with severe renal insufficiency or hepatic disease, as altered metabolism may lead to prolonged action.

Special Considerations

Pregnancy and Lactation

Insulin is the preferred glucose‑lowering agent in pregnancy due to its inability to cross the placenta and its established safety profile. Dose adjustments are often required to account for increased insulin resistance during the second and third trimesters. Insulin is considered compatible with lactation; however, monitoring of maternal glycaemia remains essential.

Paediatric Considerations

• Children require careful titration of insulin doses based on weight, growth spurts, and activity levels.
• Rapid‑acting analogues are favoured for postprandial control in children due to their safety and predictable profile.
• Insulin pens with adjustable dose increments facilitate precise dosing in paediatric populations.

Geriatric Considerations

Older adults are at increased risk for hypoglycaemia due to impaired counter‑regulatory mechanisms. Simplified basal‑bolus regimens with basal insulin analogues and lower daily doses are often employed to minimise hypoglycaemic episodes. Cognitive impairment may affect self‑administration; caregiver involvement is recommended.

Renal Impairment

Insulin clearance is reduced in chronic kidney disease. Dose adjustments are necessary, with a preference for short‑acting analogues to allow rapid titration. Monitoring of fasting glucose and post‑prandial glucose is essential to avoid hypoglycaemia.

Hepatic Impairment

In liver disease, insulin metabolism may be slowed, leading to prolonged action. Basal insulin analogues with longer half‑lives may be preferable, but careful glucose monitoring is advised.

Summary/Key Points

• Insulin preparations are classified into rapid‑acting, short‑acting, intermediate‑acting, long‑acting, and ultra‑long‑acting analogues, each with distinct pharmacokinetic profiles.
• Insulin exerts its metabolic effects through the insulin receptor, activating intracellular pathways that promote glucose uptake, glycogen synthesis, protein synthesis, and lipogenesis while inhibiting gluconeogenesis and lipolysis.
• Rapid‑acting analogues are best suited for postprandial glucose control, whereas basal insulin analogues provide background glycaemic regulation.
• Hypoglycaemia remains the most significant adverse effect; patient education and continuous glucose monitoring are essential to mitigate risk.
• Special populations, including pregnant women, children, older adults, and patients with renal or hepatic impairment, require individualized dosing strategies and close monitoring.
• Drug interactions, particularly with NSAIDs, beta‑blockers, and thyroid hormones, can modify insulin efficacy and safety; these interactions should be anticipated and managed accordingly.

Clinical pearls:

• Use insulin pens with dose‑increment features to enhance patient adherence and reduce dosing errors.
• Ingesting carbohydrate doses consistent with insulin timing can prevent postprandial hypoglycaemia.
• Implementing a structured glucose‑monitoring schedule facilitates timely dose adjustments and improves glycaemic outcomes.
• Educate patients on recognising hypoglycaemic symptoms and on the use of rapid‑acting glucose sources.
• Consider the use of ultra‑long‑acting insulin analogues in patients with erratic meal schedules to provide a stable basal insulin level.

References

1. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.